94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Domenica Lorusso1,2*
Romano Danesi3
Laura Deborah Locati4,5
Gianluca Masi6,7
Ugo De Giorgi8Angiolo Gadducci9
Sandro Pignata10Roberto Sabbatini10Antonella Savarese11
Giorgio Valabrega12Claudio Zamagni13Nicoletta Colombo14,15- 1Department of Clinical Research Planning, Fondazione Policlinico Universitario A Gemelli Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Rome, Italy
- 2Department of Life Science and Public Health, Catholic University of Sacred Heart, Rome, Italy
- 3Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- 4Translational Oncology Unit, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituti Clinici Scientifici (ICS) Maugeri, Pavia, Italy
- 5Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
- 6Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
- 7Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
- 8Department of Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy
- 9Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy
- 10Department of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricerca e Cura a carattere scientifico (IRCCS) “Fondazione Giovanni Pascale”, Naples, Italy
- 11Division of Medical Oncology 1, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) -Regina Elena National Cancer Institute, Rome, Italy
- 12University of Torino-Struttura Complessa a Direzione Universitaria (S.C.D.U.) Oncologia Azienda Ospedaliera (A.O) Ordine Mauriziano-Ospedale Umberto I, Torino, Italy
- 13Addarii Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 14School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy
- 15Department of Oncological Gynecology, European Institute of Oncology (IEO) Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Milan, Italy
A corrigendum on
Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
by Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Sabbatini R, Savarese A, Valabrega G, Zamagni C and Colombo N (2022) 12:979519. doi: 10.3389/fonc.2022.979519
In the published article, there was an error in Figure 1 as published. By mistake, we added the reference 18 for this figure. The corrected Figure 1 and its caption appear below.
In the published article, an author name was incorrectly written as Sabbatini Roberto. The correct name is Roberto Sabbatini.
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
FIGURE 1
Figure 1 Post hoc analysis of time to first onset of selected adverse reactions. Reproduced with permission from [19].
Keywords: lenvatinib, pembrolizumab, endometrial cancer, tyrosine kinase inhibitor, immune response
Citation: Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Sabbatini R, Savarese A, Valabrega G, Zamagni C and Colombo N (2023) Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. Front. Oncol. 13:1232476. doi: 10.3389/fonc.2023.1232476
Received: 31 May 2023; Accepted: 05 July 2023;
Published: 07 August 2023.
Edited and Reviewed by:
Sophia George, University of Miami, United StatesCopyright © 2023 Lorusso, Danesi, Locati, Masi, De Giorgi, Gadducci, Pignata, Sabbatini, Savarese, Valabrega, Zamagni and Colombo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Domenica Lorusso, ZG9tZW5pY2EubG9ydXNzb0Bwb2xpY2xpbmljb2dlbWVsbGkuaXQ=